Co-Diagnostics Faces Financial Challenges and Regulatory Hurdles Amidst Hold Rating

H.C. Wainwright analyst Yi Chen has reiterated their neutral stance on CODX stock, giving a Hold rating today.

Yi Chen has given his Hold rating due to a combination of factors impacting Co-Diagnostics. The company reported a net loss of $7.7 million in the second quarter of 2025, which was slightly better than expected but still indicates financial challenges. Co-Diagnostics is planning clinical evaluations for four PCR tests, including those for tuberculosis and COVID-19, with the aim of obtaining regulatory clearance by 2026. However, the company currently lacks sufficient cash flow to support its operations, necessitating a capital raise in the near term.
Yi Chen also highlighted the risks associated with Co-Diagnostics, including potential failures in clinical evaluations and securing regulatory approvals. The company’s valuation remains uncertain, as there is no current price target due to its immediate financial needs. Additionally, the risks of market competition and potential dilution further contribute to the Hold rating, as these factors could impact the company’s ability to achieve commercial success.

In another report released today, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $0.50 price target.